“We have been a little ahead of our time in the animal feed industry.” This innovative company now has a new home in Canton.
- Real Estate
- Food & Drink
Sioux Falls-based SAB Biotherapeutics is joining with global biotherapeutics leader CSL Behring to rapidly develop SAB-185, a COVID-19 therapeutic candidate on track for clinical evaluation by early summer.
Sioux Falls-based SAB Biotherapeutics will receive up to $27 million from the U.S. Department of Defense to develop and test a rapid response antibody program .
We think you’ll be encouraged by how the nation’s biotech companies — including a big player in Sioux Falls — are banding together to fight COVID-19.
SAB Biotherapeutics, a Sioux Falls immunotherapy company rapidly working to develop a therapeutic specific to COVID-19, announced it is delaying its planned development at the USD Discovery District for at least one year.
“It takes time, but we absolutely believe we are capable of producing a therapeutic response to this virus faster than anyone, and that’s what we are putting into place now.” As the world battles COVID-19, this Sioux Falls company is fighting back in a big way.